Arbutus Biopharma Corporation (ABUS)

2.7400 +0.1000 (+3.79%) As of 03:15PM EDT. Market open.

Arbutus Biopharma Corporation

701 Veterans Circle
Warminster, PA 18974
United States
267 469 0914
https://www.arbutusbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 73

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael J. McElhaugh	Co-Founder, Interim President, CEO & Director	644.4k	N/A	1975
Dr. Michael J. Sofia Ph.D.	Chief Scientific Officer	656.1k	N/A	1958
Mr. David C. Hastings CPA	CFO & Chief Accounting Officer	647.1k	N/A	1961
Ms. Lisa M. Caperelli	Vice President of Investor Relations	N/A	N/A	N/A
Mr. J. Christopher Naftzger BA, Esq., J.D.	General Counsel, Chief Compliance Officer & Secretary	N/A	N/A	1967
Ms. Shannon Briscoe SPHR	Vice President of Human Resources	N/A	N/A	N/A
Dr. Karen Sims M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1971
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.	Corporate Secretary	N/A	N/A	1951

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Corporate governance

Arbutus Biopharma Corporation’s ISS governance QualityScore as of 1 April 2024 is 6. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 9; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.